Project Grant R01HL181475
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to support research on modulating the resolution of angiogenesis and normalizing the vasculature for therapeutic benefit in cardiovascular diseases. The $549,665 award, effective January 15, 2025 through November 30, 2028, will fund research conducted by the University of Maryland, Baltimore to investigate mechanisms that regulate the resolution of angiogenesis,...
- The federal Project Grant award of $535,556.00 was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Alabama at Birmingham (UAB). The funding will support a research project to investigate the role of a novel histone modification, H3T32 O-GlcNAc, in endothelial cell dysfunction and atherosclerosis. The 5-year project aims to elucidate the epigenetic features of this histone modification under...
- The National Institutes of Health National Heart Lung and Blood Institute awarded a $511,680 Project Grant to the University of Illinois under the Cardiovascular Diseases Research program (CFDA 93.837). The grant will fund research from February 2021 through August 2021 to investigate mechanisms by which vascular endothelial cells instruct macrophage fate in inflammatory injury. Specifically, the research will examine how endothelial cell Wnt signaling licenses the differentiation of monocytes...
- The University of Maryland, Baltimore received a $678,445 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to study a novel regulator of cardiomyocyte function and homeostasis. The research aims to determine the mechanisms by which the C5ORF51 (C5X) protein modulates transcription in cardiomyocytes and investigate its role in adult cardiomyocyte proliferation and maturation. This innovative research has the potential to uncover...
- This Project Grant award, valued at $167,400.00 and awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), will support research by Brigham & Women's Hospital Inc. to investigate how the immune mediator CD70 regulates endothelial metabolism and function, with the goal of identifying novel therapeutic targets for atherosclerotic cardiovascular disease. The 5-year project will comprehensively examine the role of CD70 in impairing endothelial...
- This $548,816 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of Illinois to investigate the role of the SEC16B protein in regulating lipid metabolism and transport in the liver. The project aims to define how SEC16B mediates the formation of lipid droplets and very low-density lipoprotein (VLDL) secretion, which are key processes involved in cholesterol and triglyceride homeostasis. This...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $233,250 to the University of North Carolina at Chapel Hill (UNC-CH) to investigate the role of lipid metabolism in lung macrophage activity and phenotypes during acute lung injury. The project aims to understand how changes in lipid metabolism alter the function of lung macrophages during influenza A virus infection, which can lead to lung inflammation...
- The U.S. National Heart, Lung, and Blood Institute awarded a $803,768 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the J. David Gladstone Institutes, a non-profit biomedical research organization in California. The grant funding supports a research project titled "Chromatin Regulation of Immune Cells in Myocardial Inflammation", which aims to elucidate the role of the epigenetic regulator BRD4 in controlling monocyte differentiation and macrophage...
- The University of Texas Southwestern Medical Center received a $772,275 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct research on how endothelial cell scavenger receptor class B type I (SR-BI) is regulated and interacts with other proteins to drive LDL transcytosis and promote atherosclerosis. The award, effective August 25, 2025 through May 31, 2029, aims to determine the mechanisms by which hypercholesterolemia and...
- This Project Grant award of $715,180 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to understand the epigenetic regulation of trained immunity in thoracic aortic aneurysms and dissections. The objective is to determine how monocytes/macrophages in the aortic wall are trained to exhibit a pro-inflammatory phenotype, with the goal of identifying key pathways driving this process. The research will be conducted by Baylor...
This federal Project Grant award, provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research focused on understanding the role of the integrin receptor CD11B in atherosclerosis regression. The $752,709 grant awarded to the University of Maryland, Baltimore aims to investigate how macrophage-specific CD11B influences cholesterol efflux and inflammation, with the goal of developing new therapies to facilitate more efficient plaque regression. The award commenced in August 2025 and is scheduled for completion by May 2029. The research seeks to build on the institution's preliminary findings that suggest CD11B plays an atheroprotective function and is essential for atherosclerosis regression when LDL receptor expression is restored.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $752.7k | 8/18/25 |